title: A message from the Vioxx case.
authors.forename: H John
authors.initials: HJ
authors.lastname: Baldwin
authors.forename: Marcus
authors.initials: M
authors.lastname: Droege
authors.forename: Karen L
authors.initials: KL
authors.lastname: Daniel
mesh_terms: D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D016365:Liability, Legal; D028701:Patient Rights; D011369:Professional-Patient Relations; D018570:Risk Assessment; D013450:Sulfones / Q000009:adverse effects*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib